Alphyn Completes Enrollment in CLEAR-AD1 Global Phase 2b Clinical Trial of Novel Topical for Atopic Dermatitis

Press Release

Alphyn Completes Enrollment in CLEAR-AD1 Global Phase 2b Clinical Trial of Novel Topical for Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics Mar 11, 2026, 07:30 ET Multi-target therapeutic aims to treat all key and interconnected problems of atopic dermatitis ANNAPOLIS, Md., March 11, 2026 /PRNewswire/ — Alphyn, a clinical-stage dermatology company developing the first Multi-Target…

First Patients Dosed in Alphyn Biologics’ Phase 2 Trial of First-in-Class Topical Therapeutic for Molluscum Contagiosum

Press Release

First Patients Dosed in Alphyn Biologics’ Phase 2 Trial of First-in-Class Topical Therapeutic for Molluscum Contagiosum NEWS PROVIDED BY Alphyn Biologics Feb 18, 2026, 07:30 ET New program expands pipeline derived from Alphyn’s proprietary multi-target drug platform ANNAPOLIS, Md., Feb. 18, 2026 /PRNewswire/ — Alphyn Biologics, Inc., a clinical-stage dermatology company developing first-in-class Multi-Target Therapeutics®,…

Masters of Pediatric Dermatology 2026 Poster Presentation: S. aureus Contribution to the Etiology of Pediatric Atopic Dermatitis

Clinical Presentations

Masters of Pediatric Dermatology 2026 Poster Presentation: S. aureus Contribution to the Etiology of Pediatric Atopic Dermatitis NEWS PROVIDED BY Alphyn Biologics February 5, 2026, 00:00 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195

Masters of Pediatric Dermatology 2026 Poster Presentation: Zabalafin, a Novel Topical Antiviral for the Treatment of Molluscum Contagiosum

Clinical Presentations

Masters of Pediatric Dermatology 2026 Poster Presentation: Zabalafin, a Novel Topical Antiviral for the Treatment of Molluscum Contagiosum NEWS PROVIDED BY Alphyn Biologics February 5, 2026, 00:00 ET CONTACTS   Corporate: Neal Koller nkoller@alphynbiologics.com (410) 690-8687   Media: Susan Thomas susan@endpointcommunications.net (619) 540-9195